Literature DB >> 10195072

Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease.

R Mahadeva1, S Stewart, D Bilton, D A Lomas.   

Abstract

BACKGROUND: Alpha-1 antitrypsin (alpha 1-AT) is the most abundant proteinase inhibitor within the lung. We have recently reported the surprising observation that cystic fibrosis patients with mild to moderate deficiency of alpha 1-antitrypsin have significantly better pulmonary function than non-deficient patients. This study may have been biased as it did not include the most severely affected patients who have died in childhood or those who have undergone orthotopic lung transplantation. The prevalence of alpha 1-antitrypsin deficiency alleles in this most severely affected group of patients with cystic fibrosis was therefore assessed.
METHODS: DNA was obtained from neonatal blood spots from children with cystic fibrosis who had died from pulmonary disease and from formalin fixed lung tissue from transplanted cystic fibrosis patients. The common S and Z deficiency alleles of alpha 1-AT were sought by amplification mutagenesis of the appropriate region of the alpha 1-AT gene followed by restriction enzyme digestion with Xmn I and Taq I, respectively.
RESULTS: Seventy-nine patients were identified (seven dead, 72 transplanted). Two patients (2.5%) were heterozygous for the Z allele of alpha 1-AT and four (5.1%) were heterozygous for the S allele. This is not significantly different from the incidence in the normal population of 4% and 8% for the S and Z alleles, respectively.
CONCLUSIONS: These data support previous findings that deficiency of alpha 1-AT is not associated with more severe pulmonary disease in cystic fibrosis and may be associated with milder lung disease. Further work is needed to clarify the mechanisms underlying the progressive lung damage in cystic fibrosis.

Entities:  

Mesh:

Year:  1998        PMID: 10195072      PMCID: PMC1745129          DOI: 10.1136/thx.53.12.1022

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

1.  Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis.

Authors:  A Belaaouaj; R McCarthy; M Baumann; Z Gao; T J Ley; S N Abraham; S D Shapiro
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

2.  Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis.

Authors:  W Goldstein; G Döring
Journal:  Am Rev Respir Dis       Date:  1986-07

3.  Alpha 1-antitrypsin, emphysema and smoking.

Authors:  R W Carrell
Journal:  N Z Med J       Date:  1984-05-23

4.  Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect.

Authors:  L A Smallman; S L Hill; R A Stockley
Journal:  Thorax       Date:  1984-09       Impact factor: 9.139

5.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

6.  Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease.

Authors:  R Mahadeva; R C Westerbeek; D J Perry; J U Lovegrove; D B Whitehouse; N R Carroll; R I Ross-Russell; A K Webb; D Bilton; D A Lomas
Journal:  Eur Respir J       Date:  1998-04       Impact factor: 16.671

7.  Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis.

Authors:  S Suter; U B Schaad; J J Morgenthaler; I Chevallier; H P Schnebli
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

8.  Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa.

Authors:  S Suter; U B Schaad; H Tegner; K Ohlsson; D Desgrandchamps; F A Waldvogel
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

9.  alpha 1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis.

Authors:  D M Geddes; M Webley; D A Brewerton; C W Turton; M Turner-Warwick; A H Murphy; A M Ward
Journal:  Lancet       Date:  1977-11-19       Impact factor: 79.321

10.  Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease.

Authors:  G Döring; W Goldstein; K Botzenhart; A Kharazmi; P O Schiøtz; N Høiby; M Dasgupta
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

View more
  10 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

2.  Elevation of hepatic sulphotransferase activities in mice with resistance to cystic fibrosis.

Authors:  Josie L Falany; Heather Greer; Timea Kovacs; Eric J Sorscher; Charles N Falany
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 3.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

4.  Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis.

Authors:  R Mahadeva; L Sharples; R I Ross-Russell; A K Webb; D Bilton; D A Lomas
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

Review 5.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

Review 6.  Chronic pancreatitis and cystic fibrosis.

Authors:  H Witt
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

7.  Bioinformatic analysis of pathogenic missense mutations of activin receptor like kinase 1 ectodomain.

Authors:  Claudia Scotti; Carla Olivieri; Laura Boeri; Cecilia Canzonieri; Federica Ornati; Elisabetta Buscarini; Fabio Pagella; Cesare Danesino
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

8.  The tumor necrosis factor α (-308 A/G) polymorphism is associated with cystic fibrosis in Mexican patients.

Authors:  Celia N Sanchez-Dominguez; Miguel A Reyes-Lopez; Adriana Bustamante; Ricardo M Cerda-Flores; Maria Del C Villalobos-Torres; Hugo L Gallardo-Blanco; Augusto Rojas-Martinez; Herminia G Martinez-Rodriguez; Hugo A Barrera-Saldaña; Rocio Ortiz-Lopez
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

9.  Functional characterization of a SNP (F51S) found in human alpha 1-antitrypsin.

Authors:  Hong-Nhung Trinh; Sei-Heon Jang; ChangWoo Lee
Journal:  Mol Genet Genomic Med       Date:  2019-06-28       Impact factor: 2.183

10.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.